{"entity":{"id":"nct07243938","kind":"trial","name":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","aka":["UNION-HER2"],"tldr":"A phase 2 trial of zanidatamab, capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Tao Zhang, not yet recruiting.","summary":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) is a phase 2, interventional study registered as NCT07243938 by Tao Zhang, with a registry enrolment figure of 70 participants, started 2026-01-15 and due to reach its primary completion in 2028-07-30. Interventions recorded: short-course radiotherapy; Zanidatamab; Tisleizumab(BGB-A317); Capecitabine; Oxaliplatin; TME surgery; S-1; D2. Conditions listed: Locally Advanced Rectal Cancer (LARC); Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (mCRC); Neoadjuvant Therapy. Primary outcome: Complete Response Rate (CR Rate); Pathological Complete Response Rate (pCR Rate); Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: \"* Clinical diagnosis of gastric cancer and colorectal cancer\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07243938","url":"https://clinicaltrials.gov/study/NCT07243938"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","her2-amplified-colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["zanidatamab","capecitabine","folfox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07243938","phase":"2","setting":"A Prospective, Multi-cohort Clinical Study to Explore the Preliminary Efficacy and Safety of Zanidatamab in Combination With Tislelizumab for HER2-Positive GI Tumors: the UNION-HER2-BASKET Study","sponsor":"Tao Zhang","participation":[{"nct":"NCT07243938","source":"https://clinicaltrials.gov/study/NCT07243938","fetchedAt":"2026-10-07T16:55:34.394Z","studySha256":"24b3c76e5f1020db5331a20900c1cde1a3b35500e393261d9ff95495340ee2a1","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2025-11-24","leadSponsor":"Tao Zhang","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":70,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2026-01-15","startedType":"estimated","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07243938/","neighbours":{"cancer":[{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}